news
Scientists spotlight lung disease as fast-track model for ageing drugs
Researchers have identified idiopathic pulmonary fibrosis (IPF) as a powerful model for exploring treatments that target the biology of ageing.
List view / Grid view
Drug Discovery Processes
webinar
Pain Research: WRPRFa as a Novel Tool for Acid-Sensing Ion Channel 3 (ASIC3)
3 September 2025 | By Eurofins DiscoverX
Join this webinar to learn how WRPRFa, a novel peptide tool selective for ASIC3, advances pain research and supports drug discovery in peripheral nociceptors.
news
Three powerful antibodies discovered with potential to treat mpox
Researchers at Mount Sinai have identified three antibodies that target mpox and prevent severe disease in vivo. The work positions A35-specific antibodies as candidates for therapeutic development.
article
Inside the search-and-develop model tackling 1,000 untreated skin diseases
With over 1,000 skin diseases lacking approved treatments, a search-and-develop model is changing how new therapies are sourced and developed. Chief Scientific Officer, Jacob Pontoppidan Thyssen, outlines the strategy behind it.
news
Feline cancer breakthrough could help treat human tumours
Researchers have tested a new cancer drug in pet cats with head and neck squamous cell carcinoma – a disease notoriously hard to treat. The trial showed the therapy controlled cancer in 35 percent of cats with minimal side effects – and it could help to treat humans too.
article
Beyond the hype: a veteran’s honest assessment of AI in drug discovery – Part 3
AI is starting to transform drug discovery, but progress is still slow and big challenges remain. Thibault Géoui explores the gaps, hurdles and breakthroughs needed before it can truly change pharma R&D.
news
New M13 virus method could change future genetic treatments
Researchers at the University of Waterloo have developed a modified bacterial virus that can deliver gene therapies cheaper and more efficiently – moving us closer toward personalised, affordable genetic medicine.
news
New imaging technique tracks obesity drug tirzepatide in cells
Scientists have developed fluorescent probes that reveal how dual agonist drugs like tirzepatide target cells in the pancreas and brain, offering new insights into diabetes and obesity treatments.
article
Inside the Alzheimer’s study backing stem cells, not drugs
In this first-in-human Alzheimer’s study, Wnt-activated autologous stem cells are delivered intracerebroventricularly (directly into the brain) to address neuronal loss, while also reducing amyloid and tau biomarkers and improving cognition. Early data from this regenerative approach could help early drug discovery teams shape target selection, biomarker development and trial design.
news
Chikungunya’s 2025 surge sparks urgent research response
The 2025 chikungunya outbreak has surged from the Indian Ocean to Europe, prompting an urgent global research response. With no antivirals and limited vaccine access, laboratories and biotech firms are under pressure to deliver solutions fast.
article
Beyond the hype: a veteran’s honest assessment of AI in drug discovery – Part 2
Thibault Géoui explains why AI could finally help pharma overcome its productivity crisis and why the payoff won’t come as quickly as the optimists claim.
news
New therapy targets triglycerides to prevent aneurysms
A new study shows high triglyceride levels directly cause abdominal aortic aneurysms – highlighting triglyceride-lowering therapies as a potential new treatment.
news
From graphene to grey matter: tech that supercharges brain organoids
Researchers at UC San Diego have discovered a graphene-based technology that accelerates the maturation of human brain organoids, offering a safer, non-invasive way to model diseases like Alzheimer’s.
news
Kidney organoids reveal hidden toxicities in AAV gene therapy
Stem cell-derived kidney organoids have revealed hidden toxicities in adeno-associated virus (AAV) gene therapy delivery – offering a powerful new way to improve the safety of future treatments.
news
Planaria flatworms provide new way to study schizophrenia drugs
A new study has shown that small pond worms, called planaria, respond to psychiatric drugs like rodents – offering a promising new way of studying mental health conditions such as schizophrenia and addiction.
